News and Trends 20 Dec 2022 Verona Pharma drug meets COPD phase 3 trial endpoints …in the ENHANCE program and we look forward to keeping you updated on our progress.” Verona Pharma plans to release additional information from the ENHANCE trials at upcoming scientific conferences…. December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Interview 2 Sep 2020 An Alzheimer’s Vaccine Challenged the Consensus for 25 Years …is the premise behind Axon Neuroscience, a Slovakian biotech company founded by Michal Novak, who has been researching this molecule since the 1980s. “Our founder, Professor Michal Novak, was involved… September 2, 2020 - 8 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Weekly Roundup 10 Nov 2023 Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business… November 10, 2023 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 Sep 2025 CRISPR technology’s next wave: Ten companies to watch in 2025 …recent years, the field of CRISPR technology has improved, and different forms of the technology are now being leveraged by biotech companies. Prime editing and base editing are innovative CRISPR-related… September 30, 2025 - 15 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Inside Labiotech 28 Aug 2020 Content First: Labiotech’s Vision for 2020 and Beyond …who joined us!). Yet, these changes also led us to question our focus on events. After some internal debates, we decided to cancel future Refresh events and focus (or re-focus)… August 28, 2020 - 7 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 Jan 2025 Ten drugs to watch in 2025: will these therapies become blockbusters? …– is now poised to become a blockbuster by 2026 with analysts expecting the drug to reap $10 billion in sales in the G7 countries, namely Canada, France, Germany, Italy,… January 8, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 14 Mar 2025 Can GLP-1 agonists help treat addiction? …alcohol consumption. The company has yet to announce any significant data from this study, which only began in May last year, with an estimated completion date of January 2026. It… March 14, 2025 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
Best in Biotech 27 May 2025 Interleukin therapeutics: 9 companies to follow in 2025 …is already active in this space, but a growing number of smaller biotech companies are helping to push the field forward. In this list, we take a look at some… May 27, 2025 - 12 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Oct 2025 Five latest advancements in Tourette’s syndrome research …participants experienced a 30% decline in tic severity in 150 children with Tourette syndrome after 12 weeks back in 2023. Emboldened by the results, the Illinois-based biotech’s plans to submit the medicine for U.S. Food and Drug Administration… October 20, 2025 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2024 Fighting severe epilepsies: A new era for Dravet syndrome treatment? …often come with considerable side effects. But biotech isn’t standing idly by and several companies are taking action. The need for more effective treatments in this space is confirmed by… October 24, 2024 - 10 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 17 Dec 2024 Ovarian cancer: BioNTech, Curelab, OvarianVax and more bring vaccines to the clinic …are offered surgery, which prevents cancer but robs them of the chance to have children afterwards. At the same time, many other cases of ovarian cancer aren’t picked up until… December 17, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 24 Jul 2024 Danuglipron: Is Pfizer’s oral weight loss pill a contender in the obesity market? As the obesity drug market continues to soar, numerous biotech companies are attempting to create weight loss drugs that are either administered orally or that are more effective than Wegovy… July 24, 2024 - 10 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email